Matinas BioPharma Holdings
Market Cap
US$327.4m
Last Updated
2021/01/26 00:02 UTC
Data Sources
Company Financials +
Executive Summary
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet and slightly overvalued.
Share Price & News
How has Matinas BioPharma Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MTNB is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: MTNB's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
Market Performance
7 Day Return
0%
MTNB
3.1%
US Biotechs
2.6%
US Market
1 Year Return
7.9%
MTNB
48.3%
US Biotechs
26.0%
US Market
Return vs Industry: MTNB underperformed the US Biotechs industry which returned 48.3% over the past year.
Return vs Market: MTNB underperformed the US Market which returned 26% over the past year.
Shareholder returns
| MTNB | Industry | Market | |
|---|---|---|---|
| 7 Day | 0% | 3.1% | 2.6% |
| 30 Day | 74.9% | 8.0% | 5.1% |
| 90 Day | 84.0% | 26.9% | 17.1% |
| 1 Year | 7.9%7.9% | 50.8%48.3% | 28.9%26.0% |
| 3 Year | 43.9%43.9% | 23.7%16.9% | 46.3%36.6% |
| 5 Year | 164.5%164.5% | 59.8%47.5% | 126.9%101.6% |
Long-Term Price Volatility Vs. Market
How volatile is Matinas BioPharma Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall St
Earnings Beat: Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts3 months ago | Simply Wall St
We Think Matinas BioPharma Holdings (NYSEMKT:MTNB) Can Afford To Drive Business Growth4 months ago | Simply Wall St
How Much Is Matinas BioPharma Holdings' (NYSEMKT:MTNB) CEO Getting Paid?Valuation
Is Matinas BioPharma Holdings undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MTNB ($1.64) is trading below our estimate of fair value ($5.77)
Significantly Below Fair Value: MTNB is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MTNB is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: MTNB is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MTNB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MTNB is overvalued based on its PB Ratio (5.1x) compared to the US Biotechs industry average (4.6x).
Next Steps
Future Growth
How is Matinas BioPharma Holdings forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
64.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MTNB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MTNB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MTNB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MTNB's revenue (75.6% per year) is forecast to grow faster than the US market (10.6% per year).
High Growth Revenue: MTNB's revenue (75.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MTNB's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Matinas BioPharma Holdings performed over the past 5 years?
-7.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MTNB is currently unprofitable.
Growing Profit Margin: MTNB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MTNB is unprofitable, and losses have increased over the past 5 years at a rate of 7.5% per year.
Accelerating Growth: Unable to compare MTNB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MTNB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: MTNB has a negative Return on Equity (-31.78%), as it is currently unprofitable.
Next Steps
Financial Health
How is Matinas BioPharma Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: MTNB's short term assets ($65.2M) exceed its short term liabilities ($2.8M).
Long Term Liabilities: MTNB's short term assets ($65.2M) exceed its long term liabilities ($3.8M).
Debt to Equity History and Analysis
Debt Level: MTNB is debt free.
Reducing Debt: MTNB currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MTNB has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: MTNB has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 14.4% each year.
Next Steps
Dividend
What is Matinas BioPharma Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MTNB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MTNB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MTNB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MTNB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MTNB's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.3yrs
Average management tenure
CEO
Jerry Jabbour (46 yo)
2.83yrs
Tenure
US$1,325,176
Compensation
Mr. Jerome D. Jabbour, also known as Jerry, J.D., Co Founded Matinas BioPharma Holdings, Inc. and has been its Chief Executive Officer since March 16, 2018 and has been its President since March 7, 2016. M...
CEO Compensation Analysis
Compensation vs Market: Jerry's total compensation ($USD1.33M) is about average for companies of similar size in the US market ($USD1.65M).
Compensation vs Earnings: Jerry's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 2.83yrs | US$1.33m | 0.21% $ 695.9k | |
| Chief Financial Officer | 2yrs | US$626.60k | 0.047% $ 155.0k | |
| Chief Development Officer | 2.25yrs | US$698.14k | no data | |
| Chief Medical Officer | 1.92yrs | US$810.77k | no data | |
| Chief Technology Officer | 0.083yr | no data | no data | |
| Chief Scientific Officer | 5.33yrs | US$294.64k | 0.72% $ 2.3m | |
| Director of Investor Relations & Corporate Development | no data | no data | no data | |
| Executive Director and Head of Manufacturing & Supply Chain | 2.25yrs | no data | no data |
2.3yrs
Average Tenure
53yo
Average Age
Experienced Management: MTNB's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 2.83yrs | US$1.33m | 0.21% $ 695.9k | |
| Independent Vice Chairman of the Board | 2.33yrs | US$160.00k | 0.20% $ 656.0k | |
| Independent Chairman of the Board | 7.5yrs | US$176.00k | 2.23% $ 7.3m | |
| Independent Director | 7.17yrs | US$155.00k | 0.31% $ 1.0m | |
| Member of Scientific Advisory Board | 5.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.08yrs | no data | no data | |
| Independent Director | 3yrs | US$143.50k | 0.12% $ 400.7k | |
| Independent Director | 3.75yrs | US$151.50k | 0.058% $ 189.1k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 3yrs | no data | no data |
3.0yrs
Average Tenure
60yo
Average Age
Experienced Board: MTNB's board of directors are considered experienced (3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.4%.
Top Shareholders
Company Information
Matinas BioPharma Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Matinas BioPharma Holdings, Inc.
- Ticker: MTNB
- Exchange: AMEX
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$327.412m
- Shares outstanding: 199.64m
- Website: https://www.matinasbiopharma.com
Number of Employees
Location
- Matinas BioPharma Holdings, Inc.
- 1545 Route 206 South
- Suite 302
- Bedminster
- New Jersey
- 7921
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MTNB | AMEX (NYSE MKT LLC) | Yes | Common Stock | US | USD | Jun 2014 |
| 6LJ | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 2014 |
Biography
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC)...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/26 00:02 |
| End of Day Share Price | 2021/01/25 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.